TWI879657B - 抗體-藥物複合體 - Google Patents

抗體-藥物複合體 Download PDF

Info

Publication number
TWI879657B
TWI879657B TW113130327A TW113130327A TWI879657B TW I879657 B TWI879657 B TW I879657B TW 113130327 A TW113130327 A TW 113130327A TW 113130327 A TW113130327 A TW 113130327A TW I879657 B TWI879657 B TW I879657B
Authority
TW
Taiwan
Prior art keywords
antibody
ggfg
amino acid
group
acid sequence
Prior art date
Application number
TW113130327A
Other languages
English (en)
Chinese (zh)
Other versions
TW202448462A (zh
Inventor
益田剛
內藤博之
中田隆
吉田昌生
蘆田真二
宮崎秀樹
粕谷裕司
森田浩司
阿部有生
扇谷祐輔
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50477169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI879657(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW202448462A publication Critical patent/TW202448462A/zh
Application granted granted Critical
Publication of TWI879657B publication Critical patent/TWI879657B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW113130327A 2012-10-11 2013-10-11 抗體-藥物複合體 TWI879657B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-225887 2012-10-11
JP2012225887 2012-10-11

Publications (2)

Publication Number Publication Date
TW202448462A TW202448462A (zh) 2024-12-16
TWI879657B true TWI879657B (zh) 2025-04-01

Family

ID=50477169

Family Applications (14)

Application Number Title Priority Date Filing Date
TW102136742A TWI615152B (zh) 2012-10-11 2013-10-11 抗體－藥物複合體
TW113112336A TWI870276B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體之用途
TW113130328A TWI879658B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體
TW113130326A TWI879656B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體
TW113112335A TWI870275B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體之用途
TW113130330A TWI877062B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體
TW113130329A TWI879659B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體
TW113130327A TWI879657B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體
TW107100508A TWI650312B (zh) 2012-10-11 2013-10-11 新穎甘胺酸醯胺化合物
TW113112334A TWI870274B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體之用途
TW113130331A TWI877063B (zh) 2012-10-11 2013-10-11 抗體－藥物複合體
TW113112333A TWI870273B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體之用途
TW109116005A TWI757740B (zh) 2012-10-11 2013-10-11 甘胺酸醯胺化合物及其製造方法
TW108100079A TWI696611B (zh) 2012-10-11 2013-10-11 甘胺酸醯胺化合物的製造方法

Family Applications Before (7)

Application Number Title Priority Date Filing Date
TW102136742A TWI615152B (zh) 2012-10-11 2013-10-11 抗體－藥物複合體
TW113112336A TWI870276B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體之用途
TW113130328A TWI879658B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體
TW113130326A TWI879656B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體
TW113112335A TWI870275B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體之用途
TW113130330A TWI877062B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體
TW113130329A TWI879659B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體

Family Applications After (6)

Application Number Title Priority Date Filing Date
TW107100508A TWI650312B (zh) 2012-10-11 2013-10-11 新穎甘胺酸醯胺化合物
TW113112334A TWI870274B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體之用途
TW113130331A TWI877063B (zh) 2012-10-11 2013-10-11 抗體－藥物複合體
TW113112333A TWI870273B (zh) 2012-10-11 2013-10-11 抗體-藥物複合體之用途
TW109116005A TWI757740B (zh) 2012-10-11 2013-10-11 甘胺酸醯胺化合物及其製造方法
TW108100079A TWI696611B (zh) 2012-10-11 2013-10-11 甘胺酸醯胺化合物的製造方法

Country Status (30)

Country Link
US (6) US10195288B2 (enExample)
EP (3) EP2907824B1 (enExample)
JP (9) JP5953378B2 (enExample)
KR (15) KR102709509B1 (enExample)
CN (4) CN104755494B (enExample)
AU (5) AU2013328111B2 (enExample)
BR (3) BR112015006521B1 (enExample)
CA (2) CA3021435C (enExample)
CY (2) CY1120363T1 (enExample)
DK (2) DK2907824T3 (enExample)
ES (2) ES2773710T3 (enExample)
HR (2) HRP20180870T1 (enExample)
HU (2) HUE039000T2 (enExample)
IL (5) IL271760B (enExample)
LT (2) LT3342785T (enExample)
MX (3) MX364484B (enExample)
MY (1) MY170251A (enExample)
NZ (4) NZ746439A (enExample)
PH (2) PH12015500667B1 (enExample)
PL (2) PL3342785T3 (enExample)
PT (2) PT2907824T (enExample)
RS (2) RS57278B1 (enExample)
RU (1) RU2664465C2 (enExample)
SG (2) SG11201502887WA (enExample)
SI (2) SI3342785T1 (enExample)
SM (2) SMT202000138T1 (enExample)
TR (1) TR201809636T4 (enExample)
TW (14) TWI615152B (enExample)
WO (1) WO2014057687A1 (enExample)
ZA (2) ZA201501825B (enExample)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014057687A1 (ja) * 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
SI3424955T1 (sl) 2013-12-25 2025-08-29 Daiichi Sankyo Company, Limited Metoda za proizvodnjo konjugata protitelo-zdravilo anti-trop2
SI3101032T1 (sl) 2014-01-31 2019-02-28 Daiichi Sankyo Company, Limited Konjugat zdravila s protitelesci ANTI-HER2
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
SMT202500021T1 (it) * 2014-04-10 2025-03-12 Daiichi Sankyo Co Ltd Metodo per produrre un coniugato anticorpo anti-her3-farmaco
JP6612738B2 (ja) * 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
US11173213B2 (en) * 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
WO2017110923A1 (ja) * 2015-12-24 2017-06-29 旭硝子株式会社 樹脂組成物、基材および細胞培養方法
PE20190353A1 (es) * 2016-04-15 2019-03-07 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
MY199278A (en) * 2016-06-08 2023-10-24 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
MX2018015277A (es) * 2016-06-08 2019-09-06 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
CN107840892A (zh) * 2016-09-20 2018-03-27 上海药明生物技术有限公司 新型抗‑pcsk9抗体
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
CN110382535A (zh) * 2017-01-17 2019-10-25 第一三共株式会社 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
AU2018227146B2 (en) 2017-02-28 2025-04-03 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
TW202530219A (zh) * 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
TW201909926A (zh) * 2017-08-04 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
CA3073383C (en) * 2017-08-23 2023-10-31 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
WO2019044946A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
JP7366745B2 (ja) * 2017-08-31 2023-10-23 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
CA3126646A1 (en) 2017-09-29 2019-04-04 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CN111542324B (zh) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
US12479926B2 (en) 2018-05-18 2025-11-25 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
WO2020022363A1 (ja) 2018-07-25 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの効果的な製造方法
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
CN112805036A (zh) 2018-07-31 2021-05-14 第一三共株式会社 通过施用抗体-药物缀合物对转移性脑肿瘤的治疗
EP3834843A4 (en) * 2018-08-06 2022-05-11 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR
US12312641B2 (en) 2018-08-23 2025-05-27 Daiichi Sankyo Company, Limited Sensitivity marker for antibody-drug conjugate
IL281247B2 (en) 2018-09-06 2025-01-01 Daiichi Sankyo Co Ltd Novel cyclic dinucleotide derivatives and their antibody-drug conjugates
JPWO2020059772A1 (ja) 2018-09-20 2021-08-30 第一三共株式会社 抗ｈｅｒ３抗体−薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
EP3858386A4 (en) * 2018-09-26 2022-10-12 Jiangsu Hengrui Medicine Co., Ltd. LIGAND-DRUG CONJUGATE OF AN EXATECAN ANALOG, METHOD FOR PREPARATION AND THEIR USE
AU2019351427A1 (en) * 2018-09-30 2021-04-15 Changzhou Hansoh Pharmaceutical Co., Ltd. Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
SG11202104993SA (en) 2018-11-14 2021-06-29 Daiichi Sankyo Co Ltd Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
EA202191641A1 (ru) * 2018-12-11 2021-09-13 Дайити Санкио Компани, Лимитед Комбинация конъюгата антитело-лекарственное средство с ингибитором parp
AU2019407426A1 (en) * 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
JP7682797B2 (ja) 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
AU2020241896A1 (en) 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
KR20240104214A (ko) * 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
WO2020259258A1 (zh) * 2019-06-28 2020-12-30 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
CN117731798A (zh) * 2019-06-28 2024-03-22 泰州复旦张江药业有限公司 抗体偶联药物、其中间体、制备方法及应用
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
CR20220058A (es) 2019-07-10 2022-07-19 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos
EP4032892A4 (en) * 2019-09-18 2023-10-18 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. CAMPTOTHECIN DERIVATIVE AND CONJUGATE THEREOF
KR20220113728A (ko) 2019-12-12 2022-08-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항 클라우딘 항체 약물 접합체 및 그 의약 용도
UA129521C2 (uk) * 2019-12-16 2025-05-21 Джянгсу Хенгруй Медісін Ко., Лтд. Аналог кон'югата анти-сеа антитілo-ексатекан та його фармацевтичне застосування
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021148003A1 (zh) 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
CN118873679A (zh) 2020-01-22 2024-11-01 江苏恒瑞医药股份有限公司 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
CN115551552A (zh) 2020-02-25 2022-12-30 祐方有限公司 喜树碱衍生物及其缀合物
KR20220151630A (ko) 2020-03-06 2022-11-15 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체를 포함하는 항체 약물 컨쥬게이트
WO2021190480A1 (zh) * 2020-03-24 2021-09-30 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
WO2021190581A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
BR112022019042A2 (pt) * 2020-03-25 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Método de preparação para conjugado anticorpo-fármaco
CA3177279A1 (en) * 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
CA3173263A1 (en) 2020-03-30 2021-10-07 Yasuhiro Matsumura Antibody drug conjugate
AU2021289927A1 (en) * 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
IL299368A (en) 2020-06-24 2023-02-01 Astrazeneca Uk Ltd A combination of an antibody-drug conjugate and an ATR inhibitor
TW202216207A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及cdk9抑制劑之組合
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
US10997243B1 (en) 2020-06-30 2021-05-04 Snowflake Inc. Supporting unstructured, semi-structured, and structured files
US11361026B2 (en) 2020-06-30 2022-06-14 Snowflake Inc. Accessing files in a database stage using a user defined function
US11423081B1 (en) 2020-06-30 2022-08-23 Snowflake Inc. Accessing files in a database stage using a user defined function
KR20230035332A (ko) 2020-07-06 2023-03-13 비온디스 비.브이. 항엽산제 링커-약물 및 항체-약물 접합체
WO2022011075A1 (en) * 2020-07-10 2022-01-13 VelosBio Inc. Novel ror1 antibody immunoconjugates
WO2022015656A1 (en) * 2020-07-13 2022-01-20 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
BR112023000711A2 (pt) 2020-07-17 2023-01-31 Daiichi Sankyo Co Ltd Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco
CN115702008B (zh) 2020-08-13 2024-12-06 正大天晴药业集团股份有限公司 抗体药物偶联物
JP2023537115A (ja) 2020-08-13 2023-08-30 イナート・ファルマ・ソシエテ・アノニム 抗ｃｄ７３抗体を使用する癌処置方法
CN116113641A (zh) 2020-09-02 2023-05-12 第一三共株式会社 新型内－β－N－乙酰氨基葡萄糖苷酶
CN116199739B (zh) 2020-09-30 2024-12-17 映恩生物制药（苏州）有限公司 一种抗肿瘤化合物及其制备方法和应用
KR20230084163A (ko) 2020-10-09 2023-06-12 아스트라제네카 유케이 리미티드 항체-약물 접합체와 parp1 선택적 억제제의 조합
IL302054A (en) * 2020-10-12 2023-06-01 Sichuan Baili Pharm Co Ltd Camptothecin derivative and ligand-drug conjugate thereof
IL302053A (en) * 2020-10-12 2023-06-01 Sichuan Baili Pharm Co Ltd Camptothecin derivative is canceled and their conjugation to anti-body drugs
AU2021378152A1 (en) 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
WO2022099762A1 (zh) * 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
US20230398230A1 (en) * 2020-11-12 2023-12-14 Daiichi Sankyo Company, Limited Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
US20240050584A1 (en) * 2020-12-18 2024-02-15 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Trop2 targeting antibody-drug conjugate, and preparation method and use therefor
WO2022126569A1 (zh) * 2020-12-18 2022-06-23 上海复旦张江生物医药股份有限公司 一种靶向b7-h3的抗体药物偶联物、其制备方法及应用
EP4267140A4 (en) * 2020-12-23 2025-02-26 Shanghai Ruotuo Biosciences Co., Ltd. ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
JP2024503658A (ja) * 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗ｄｌｌ３抗体－薬物コンジュゲート
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
CN115279417B (zh) 2021-02-09 2025-01-03 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
IL305816A (en) 2021-03-12 2023-11-01 Daiichi Sankyo Co Ltd Glycan and a method for preparing a medicine containing it
CN117015549A (zh) * 2021-03-17 2023-11-07 江苏恒瑞医药股份有限公司 一种喜树碱衍生物的制备方法
WO2022198231A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
CN115197234A (zh) * 2021-04-02 2022-10-18 江苏恒瑞医药股份有限公司 一种喜树碱衍生物中间体的制备方法
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
AU2022259314A1 (en) * 2021-04-14 2023-11-30 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
EP4079327A1 (en) 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
AU2022262644A1 (en) 2021-04-23 2023-11-09 Genmab A/S Anti-cd70 antibodies, conjugates thereof and methods of using the same
CN116917324A (zh) * 2021-04-26 2023-10-20 江苏恒瑞医药股份有限公司 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途
CN113816969B (zh) * 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
US11645243B2 (en) 2021-06-07 2023-05-09 Snowflake Inc. Accessing files in a database stage using a user defined function
EP4357348A1 (en) * 2021-06-17 2024-04-24 Minghui Pharmaceutical (Hangzhou) Ltd. Antitumor compound and use thereof
BR112023026735A2 (pt) 2021-06-28 2024-03-12 Byondis Bv Conjugado, composto de conector-fármaco, uso de um composto de conector-fármaco, e, composição farmacêutica
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN113402584A (zh) * 2021-07-06 2021-09-17 联宁（苏州）生物制药有限公司 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CN113527418B (zh) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 一种ADC linker的制备方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
US20230123041A1 (en) * 2021-07-19 2023-04-20 Recurium Ip Holdings, Llc Immunoconjugates and methods
EP4374874A4 (en) 2021-07-21 2025-08-06 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY-DRUG CONJUGATE AND ITS APPLICATION
US20240390512A1 (en) 2021-09-15 2024-11-28 Daiichi Sankyo Company, Limited Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate
WO2023054706A1 (ja) 2021-09-30 2023-04-06 味の素株式会社 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
EP4420683A1 (en) 2021-10-18 2024-08-28 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
MX2024005831A (es) 2021-11-15 2024-07-09 Systimmune Inc Conjugado de anticuerpo biespecifico-farmaco de camptotecina y uso farmaceutico del mismo.
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
TW202329936A (zh) 2021-11-18 2023-08-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與parp1選擇性抑制劑之組合
JP2024540536A (ja) 2021-11-19 2024-10-31 アーディアジェン コーポレーション Ｇｐｃ３結合剤、そのコンジュゲートおよびその使用方法
AU2022401024A1 (en) 2021-11-30 2024-05-16 Daiichi Sankyo Company, Limited Protease-cleavable masked antibodies
CA3245264A1 (en) 2021-12-03 2025-06-13 Systimmune, Inc. Conjugated Anti-Trop2 Human Antibody-Camptothecine Drug and its Medical Use
TW202346346A (zh) 2021-12-23 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途
EP4455164A1 (en) * 2021-12-24 2024-10-30 Bio-Thera Solutions, Ltd. ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
US20250161305A1 (en) 2021-12-28 2025-05-22 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
US20250064967A1 (en) 2021-12-28 2025-02-27 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
US20250114466A1 (en) 2021-12-30 2025-04-10 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
EP4494657A1 (en) * 2022-01-18 2025-01-22 Gan & Lee Pharmaceuticals Co., Ltd. Exatecan derivative-antibody conjugate and medical use thereof
IL314470A (en) 2022-01-25 2024-09-01 Medilink Therapeutics Suzhou Co Ltd Anti-Her3 antibody, conjugate and use thereof
EP4477674A1 (en) 2022-02-09 2024-12-18 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
CN119156232A (zh) 2022-02-28 2024-12-17 Ｕｂｅ株式会社 抗体-药物偶联物前体及其合成中间体
KR20240151847A (ko) 2022-02-28 2024-10-18 유비이 가부시키가이샤 항체-약물 콘쥬게이트
CN118804983A (zh) 2022-03-02 2024-10-18 第一三共株式会社 含Fc分子的制造方法
JP2025509286A (ja) 2022-03-10 2025-04-11 ビバソル， インコーポレイテッド 抗体－薬物コンジュゲートおよびその使用
JP2025509564A (ja) 2022-03-16 2025-04-11 アストラゼネカ ユーケー リミテッド 抗ｔｒｏｐ２抗体－薬物コンジュゲート治療のためのスコアリング方法
TWI864640B (zh) 2022-03-18 2024-12-01 大陸商映恩生物製藥（蘇州）有限公司 Gpc3抗體藥物偶聯物及其用途
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CA3249707A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR
EP4522658A1 (en) 2022-05-11 2025-03-19 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
CA3256230A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited DOSAGE REGIMEN OF AN ANTI-CDH6 ANTIBODY-DRUG CONJUGATE
JPWO2023234427A1 (enExample) 2022-06-03 2023-12-07
AU2023279443A1 (en) 2022-06-03 2025-01-23 Ube Corporation Antibody-multidrug conjugate
EP4537853A1 (en) 2022-06-07 2025-04-16 Duality Biologics (Suzhou) Co., Ltd. Anti-b7h3 antibody-drug conjugate and use thereof
KR20250020660A (ko) * 2022-06-09 2025-02-11 베이진 엘티디 항체 약물 접합체
CN119365216A (zh) 2022-06-15 2025-01-24 上海翰森生物医药科技有限公司 一种含抗体药物偶联物的药物组合物及其用途
CN118955615A (zh) * 2022-07-05 2024-11-15 上海药明合联生物技术有限公司 偶联连接子
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
WO2024014837A1 (ko) 2022-07-11 2024-01-18 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭
AU2023307126A1 (en) 2022-07-14 2025-02-13 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate, and preparation method therefor and use thereof
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2024020536A1 (en) * 2022-07-22 2024-01-25 Nj Bio, Inc. Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
EP4563163A1 (en) 2022-07-27 2025-06-04 Minghui Pharmaceutical (Hangzhou) Limited Antibody-drug conjugate and use thereof
TW202412859A (zh) 2022-07-28 2024-04-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及雙特異性檢查點抑制劑之組合
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
PE20251067A1 (es) 2022-08-02 2025-04-09 Nona Biosciences Suzhou Co Ltd Conjugado anticuerpo-farmaco msln
JP2025531032A (ja) 2022-08-25 2025-09-19 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー． 抗体薬物複合体の医薬組成物
TW202417056A (zh) 2022-08-29 2024-05-01 日商第一三共股份有限公司 包含變異Fc區域的抗體藥物結合物
JP2025511436A (ja) 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
WO2024053574A1 (ja) 2022-09-09 2024-03-14 第一三共株式会社 新規なオリゴ糖、該オリゴ糖の製造中間体、及びそれらの製造方法
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
JP2025533594A (ja) * 2022-09-26 2025-10-07 ソルブ セラピューティクス，インク． 組成物およびその使用
AU2023349279A1 (en) * 2022-09-30 2025-05-15 Beone Medicines I Gmbh Ligand-drug conjugate of exatecan analogue, and medical use thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
JP2025533191A (ja) 2022-10-09 2025-10-03 ラノバ メディシンズ リミテッド 化合物、組成物および方法
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
TW202434306A (zh) 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 抗ｃｅａ抗體藥物軛合物及使用方法
WO2024109949A1 (zh) * 2022-11-25 2024-05-30 明慧医药（杭州）有限公司 一种抗肿瘤化合物及其应用
WO2024114318A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
CN120282803A (zh) 2022-11-30 2025-07-08 第一三共株式会社 抗体-药物缀合物和dnmt抑制剂的组合
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN116621927B (zh) * 2023-01-09 2024-03-26 联宁（苏州）生物制药有限公司 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物
IL322569A (en) 2023-02-09 2025-10-01 Beone Medicines I Gmbh Self-stabilizing bonding material bracelets
WO2024179470A1 (zh) * 2023-02-27 2024-09-06 苏州盛迪亚生物医药有限公司 抗dll3抗体、其抗体-药物偶联物及其医药用途
TW202444423A (zh) 2023-03-14 2024-11-16 日商第一三共股份有限公司 抗cdh6抗體-藥物結合物與vegf抑制劑之組合
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
TW202438114A (zh) * 2023-03-23 2024-10-01 瑞士商百濟神州瑞士有限責任公司 生物活性結合物、其製備方法及其用途
CN120917143A (zh) 2023-03-29 2025-11-07 第一三共株式会社 抗cd25抗体及抗cd25抗体-药物偶联物
AU2024248799A1 (en) 2023-03-31 2025-10-23 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor
KR20250172615A (ko) 2023-04-04 2025-12-09 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트, 항체 유도체 및 화합물, 또는 그것들의 염
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
KR20250167673A (ko) 2023-04-05 2025-12-01 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트 또는 그 염, 및 티올기를 갖는 항체 중간체 또는 그 염
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
TW202446421A (zh) 2023-04-10 2024-12-01 日商第一三共股份有限公司 抗ｂ７－ｈ３抗體－藥物結合物與ａｔｒ抑制劑或ａｔｍ抑制劑之組合
CN121127269A (zh) 2023-04-13 2025-12-12 启德医药科技（苏州）有限公司 抗体-药物偶联物和抗pd-1抗体的组合及其用途
AU2024270034A1 (en) 2023-05-06 2025-12-04 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Deuterated camptothecin compound, and preparation therefor and use thereof
WO2024230752A1 (zh) 2023-05-08 2024-11-14 甘李药业股份有限公司 喜树碱衍生物、接头、配体-药物偶联物及其医药用途
AU2024273972A1 (en) * 2023-05-16 2025-12-04 CSPC Megalith Biopharmaceutical Co., Ltd. Pharmaceutical composition comprising antibody-drug conjugate
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof
WO2025002310A1 (zh) * 2023-06-29 2025-01-02 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
WO2025005240A1 (ja) * 2023-06-30 2025-01-02 第一三共株式会社 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
WO2025036480A1 (zh) * 2023-08-16 2025-02-20 中山康方生物医药有限公司 化合物以及含有该化合物的抗体偶联药物
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
WO2025141153A1 (en) 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
WO2025146131A1 (en) 2024-01-05 2025-07-10 Beigene, Ltd. ANTI-FGFR2b ANTIBODIES, CONJUGATES AND METHODS OF USE
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
WO2025185559A1 (zh) * 2024-03-04 2025-09-12 杭州中美华东制药有限公司 抗FGFR2b抗体、其抗体药物偶联物及其用途
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
WO2025241867A1 (zh) * 2024-05-24 2025-11-27 明慧医药（杭州）有限公司 抗b7-h4抗体药物偶联物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI232930B (en) * 1998-10-30 2005-05-21 Daiichi Seiyaku Co Method for measuring drug delivery system compound (DDS)

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5637770A (en) * 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JPH0559061U (ja) 1991-04-18 1993-08-03 株式会社ケイヴイシー ボールバルブ
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0687746U (ja) 1993-06-02 1994-12-22 株式会社ユニシアジェックス 液圧緩衝器のリザーバチューブ構造
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JPH08337584A (ja) 1995-04-10 1996-12-24 Dai Ichi Seiyaku Co Ltd 縮合六環式アミノ化合物、これを含有する医薬及びその製法
US6504029B1 (en) * 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JPH1095802A (ja) 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd カンプトテシン誘導体
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
JPH1171280A (ja) 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
JPH1192405A (ja) * 1997-09-19 1999-04-06 Dai Ichi Seiyaku Co Ltd 薬物複合体
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1080732A4 (en) * 1998-05-22 2004-08-25 Daiichi Seiyaku Co DRUG COMPOSITION
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
JP2002060351A (ja) 2000-03-22 2002-02-26 Dai Ichi Seiyaku Co Ltd 水酸基を有する薬物を含むｄｄｓ化合物
IL153505A0 (en) * 2000-06-29 2003-07-06 Daiichi Seiyaku Co Dds compound and process for the preparation thereof
RU2003100532A (ru) 2000-07-13 2004-07-20 Дайити Фармасьютикал Ко., Лтд. (JP) Фармацевтические композиции, содержащие соединение соединения dds
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
EP1482972A4 (en) * 2001-11-20 2005-11-23 Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
WO2006113909A2 (en) 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
EP2033645A1 (en) 2004-02-26 2009-03-11 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EP1725586B1 (en) 2004-03-02 2015-01-14 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
DE102005009084A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel
DE102005009099A1 (de) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ZA200809776B (en) 2006-05-30 2010-03-31 Genentech Inc Antibodies and immunoconjugates and uses therefor
NZ597251A (en) * 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
JPWO2007145306A1 (ja) * 2006-06-15 2009-11-12 国立大学法人 北海道大学 腫瘍組織で選択的に分解性を示す血中滞留性素子
ITMI20061473A1 (it) * 2006-07-26 2008-01-27 Indena Spa Derivati della camptotecina ad attivita antitumorale
CA2673410A1 (en) 2006-12-21 2008-07-03 Schering Corporation Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity
WO2008116219A2 (en) * 2007-03-22 2008-09-25 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
RU2503687C2 (ru) 2008-04-30 2014-01-10 Иммьюноджен, Инк. Сшивающие реагенты и их применение
CA2750038C (en) 2009-02-05 2016-10-04 Oncoxx S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
WO2011021397A1 (ja) 2009-08-20 2011-02-24 国立大学法人千葉大学 コルヒチン誘導体
JP2013505944A (ja) 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド Ｄｒ５リガンド薬物結合体
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
CN105797168A (zh) 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
CA2804185C (en) 2010-07-12 2017-03-21 Covx Technologies Ireland Limited Multifunctional antibody conjugates
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
KR20140091040A (ko) 2011-11-11 2014-07-18 리나트 뉴로사이언스 코프. Trop-2에 특이적인 항체 및 그의 용도
JP2015505850A (ja) 2011-12-14 2015-02-26 シアトル ジェネティックス， インコーポレイテッド 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
US20130280282A1 (en) 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
WO2013188740A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
US9517522B2 (en) * 2012-09-05 2016-12-13 Illinois Tool Works Inc. Self-aligning wire feeder assembly
WO2014057687A1 (ja) * 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
CN105051032B (zh) 2013-01-03 2017-08-15 赛特瑞恩股份有限公司 抗体‑连接子‑药物偶联物、其制法及包含其的抗癌药物组合物
CN103313390B (zh) 2013-07-05 2016-01-20 江苏大学 一种基于双移动信标的wsn定位方法
SI3101032T1 (sl) 2014-01-31 2019-02-28 Daiichi Sankyo Company, Limited Konjugat zdravila s protitelesci ANTI-HER2
JP6612738B2 (ja) 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
KR102199434B1 (ko) 2017-02-24 2021-01-06 장길훈 대화형 애플리케이션의 메시지 공유 시스템과 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI232930B (en) * 1998-10-30 2005-05-21 Daiichi Seiyaku Co Method for measuring drug delivery system compound (DDS)

Also Published As

Publication number Publication date
AU2022203560A1 (en) 2022-06-16
IL238143B (en) 2020-01-30
IL238143A0 (en) 2015-05-31
US10195288B2 (en) 2019-02-05
ZA201501825B (en) 2022-05-25
IL302494B2 (en) 2024-11-01
JP6952835B2 (ja) 2021-10-27
KR102456726B1 (ko) 2022-10-20
PT2907824T (pt) 2018-06-07
BR112015006521A2 (enExample) 2017-09-05
HRP20200353T1 (hr) 2020-06-12
SMT201800344T1 (it) 2018-09-13
TWI696611B (zh) 2020-06-21
KR20180105271A (ko) 2018-09-27
JP7523506B2 (ja) 2024-07-26
MX2019004502A (es) 2019-08-21
TW202444429A (zh) 2024-11-16
HUE048748T2 (hu) 2020-08-28
RU2018128384A3 (enExample) 2021-12-20
MX364484B (es) 2019-04-29
KR102709509B1 (ko) 2024-09-24
TW202233186A (zh) 2022-09-01
KR102540419B1 (ko) 2023-06-05
RS57278B1 (sr) 2018-08-31
IL271760A (en) 2020-02-27
TWI870275B (zh) 2025-01-11
JP7170812B2 (ja) 2022-11-14
US12186310B2 (en) 2025-01-07
TW202448522A (zh) 2024-12-16
TR201809636T4 (tr) 2018-07-23
TW202448521A (zh) 2024-12-16
BR122021014365B1 (pt) 2022-07-05
HRP20180870T1 (hr) 2018-07-13
AU2022203560B2 (en) 2025-02-06
PT3342785T (pt) 2020-02-25
EP2907824B1 (en) 2018-04-11
HK1210477A1 (en) 2016-04-22
LT3342785T (lt) 2020-02-10
RU2015113767A (ru) 2016-12-10
JP2023011799A (ja) 2023-01-24
AU2013328111B2 (en) 2017-11-02
LT2907824T (lt) 2018-06-11
TWI870273B (zh) 2025-01-11
MY170251A (en) 2019-07-13
CN104755494B (zh) 2018-09-07
SG10201804788XA (en) 2018-07-30
KR102087017B1 (ko) 2020-03-10
KR102498405B1 (ko) 2023-02-09
AU2018200308B2 (en) 2019-11-07
JP6030267B1 (ja) 2016-11-24
KR20210132240A (ko) 2021-11-03
PH12015500667A1 (en) 2015-05-18
PH12015500667B1 (en) 2019-03-06
EP2907824A4 (en) 2016-06-08
TWI870276B (zh) 2025-01-11
NZ705394A (en) 2018-10-26
MX2015003903A (es) 2015-07-17
TWI877063B (zh) 2025-03-11
CN109081871A (zh) 2018-12-25
AU2020200548A1 (en) 2020-02-13
JP6186045B2 (ja) 2017-08-23
KR102237639B1 (ko) 2021-04-07
IL302494A (en) 2023-06-01
AU2025202668A1 (en) 2025-07-03
KR102417310B1 (ko) 2022-07-05
AU2018200308A1 (en) 2018-02-01
KR20230024433A (ko) 2023-02-20
JP2016196484A (ja) 2016-11-24
US20150297748A1 (en) 2015-10-22
BR112015006521B1 (pt) 2022-03-03
JP2018008982A (ja) 2018-01-18
US20240082413A1 (en) 2024-03-14
CA2885800A1 (en) 2014-04-17
JP5953378B2 (ja) 2016-07-20
EP3632471A1 (en) 2020-04-08
JP2017036274A (ja) 2017-02-16
US20200282073A1 (en) 2020-09-10
MX2020010964A (es) 2020-11-09
KR102584005B1 (ko) 2023-09-27
CY1122789T1 (el) 2021-05-05
KR102369419B1 (ko) 2022-03-02
TWI879656B (zh) 2025-04-01
KR20150067149A (ko) 2015-06-17
CA3021435C (en) 2021-10-12
TW201811746A (zh) 2018-04-01
KR20210038728A (ko) 2021-04-07
TWI879659B (zh) 2025-04-01
PL2907824T3 (pl) 2018-08-31
TW202444366A (zh) 2024-11-16
RU2018128384A (ru) 2018-10-02
SI3342785T1 (sl) 2020-02-28
TWI757740B (zh) 2022-03-11
TW202444367A (zh) 2024-11-16
RS60000B1 (sr) 2020-04-30
CN115960111A (zh) 2023-04-14
CA3021435A1 (en) 2014-04-17
TW201920098A (zh) 2019-06-01
IL294622B1 (en) 2023-06-01
US20190008981A1 (en) 2019-01-10
TW202033499A (zh) 2020-09-16
IL294622A (en) 2022-09-01
IL302494B1 (en) 2024-07-01
TW202448464A (zh) 2024-12-16
SMT202000138T1 (it) 2020-05-08
TW201420117A (zh) 2014-06-01
TW202444428A (zh) 2024-11-16
KR20200026323A (ko) 2020-03-10
SI2907824T1 (en) 2018-06-29
US9808537B2 (en) 2017-11-07
JP6715888B2 (ja) 2020-07-01
US10973924B2 (en) 2021-04-13
IL313147A (en) 2024-07-01
KR20190135559A (ko) 2019-12-06
NZ746440A (en) 2019-11-29
CN113929738B (zh) 2024-05-17
TW202448463A (zh) 2024-12-16
RU2664465C2 (ru) 2018-08-17
JP6371452B2 (ja) 2018-08-08
CA2885800C (en) 2018-12-04
KR102052319B1 (ko) 2019-12-05
CN109081871B (zh) 2023-07-14
KR101901558B1 (ko) 2018-09-21
KR20250130442A (ko) 2025-09-01
DK2907824T3 (en) 2018-07-23
IL294622B2 (en) 2023-10-01
TW202448523A (zh) 2024-12-16
KR20230086800A (ko) 2023-06-15
HUE039000T2 (hu) 2018-12-28
EP3342785B1 (en) 2019-12-25
EP3342785A1 (en) 2018-07-04
ZA201900820B (en) 2022-08-31
US11633493B2 (en) 2023-04-25
DK3342785T3 (da) 2020-03-23
KR20220029776A (ko) 2022-03-08
BR122021014396B1 (pt) 2022-07-05
CN104755494A (zh) 2015-07-01
TWI879658B (zh) 2025-04-01
ES2773710T3 (es) 2020-07-14
US20250049782A1 (en) 2025-02-13
TWI650312B (zh) 2019-02-11
JP2022008581A (ja) 2022-01-13
JP2024147681A (ja) 2024-10-16
JP2020180124A (ja) 2020-11-05
KR20230142808A (ko) 2023-10-11
KR20240144454A (ko) 2024-10-02
PL3342785T3 (pl) 2020-09-07
PH12018501433A1 (en) 2019-02-27
JPWO2014057687A1 (ja) 2016-09-05
KR102320907B1 (ko) 2021-11-02
NZ746439A (en) 2019-11-29
TW202448462A (zh) 2024-12-16
KR102853456B1 (ko) 2025-09-01
KR101841818B1 (ko) 2018-03-26
EP2907824A1 (en) 2015-08-19
US20160279259A1 (en) 2016-09-29
IL271760B (en) 2022-08-01
CY1120363T1 (el) 2019-07-10
AU2020200548B2 (en) 2022-08-25
TWI615152B (zh) 2018-02-21
KR20220146669A (ko) 2022-11-01
JP2018188455A (ja) 2018-11-29
CN113929738A (zh) 2022-01-14
TWI870274B (zh) 2025-01-11
AU2013328111A1 (en) 2015-03-12
KR20180030734A (ko) 2018-03-23
WO2014057687A1 (ja) 2014-04-17
NZ740948A (en) 2019-11-29
SG11201502887WA (en) 2015-05-28
KR20220100727A (ko) 2022-07-15
HK1256631A1 (en) 2019-09-27
ES2671644T3 (es) 2018-06-07
TWI877062B (zh) 2025-03-11

Similar Documents

Publication Publication Date Title
TWI879657B (zh) 抗體-藥物複合體
TWI907646B (zh) 依喜替康（exatecan）衍生物之用途
TW202543629A (zh) 用以製造抗體－藥物複合體之方法